» Articles » PMID: 8808429

Effects of Ursodeoxycholic Acid and Chenodeoxycholic Acid on Major Histocompatibility Complex Class I Gene Expression

Overview
Journal J Gastroenterol
Specialty Gastroenterology
Date 1996 Feb 1
PMID 8808429
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

We investigated the effect of ursodeoxycholic acid on major histocompatibility complex class I gene expression in cultured human hepatoma cells. Ursodeoxycholic acid, which is now being used for the treatment of various autoimmune liver diseases, paradoxically increased the mRNA level of major histocompatibility complex class I. However, endogenous bile acids, for example, chenodeoxycholic acid, increased major histocompatibility complex class I mRNA expression more strongly compared with ursodeoxycholic acid. Concerning the interplay between ursodeoxycholic and chenodeoxycholic acids, these bile acids additively induced major histocompatibility complex class I mRNA expression. In contrast, when the total concentration of ursodeoxycholic and chenodeoxycholic acids was kept constant, the expression of major histocompatibility complex class I mRNA appeared to decrease in a dose-dependent manner with an increasing ratio of ursodeoxycholic acid. These findings indicate that the beneficial action of ursodeoxycholic acid may be related to this relative decrease in major histocompatibility complex class I gene expression.

Citing Articles

Ursodeoxycholic Acid in Treatment of Non-cholestatic Liver Diseases: A Systematic Review.

Reardon J, Hussaini T, Alsahafi M, Marquez Azalgara V, Erb S, Partovi N J Clin Transl Hepatol. 2016; 4(3):192-205.

PMID: 27777888 PMC: 5075003. DOI: 10.14218/JCTH.2016.00023.


The management of primary sclerosing cholangitis.

Chapman R Curr Gastroenterol Rep. 2003; 5(1):9-17.

PMID: 12530943 DOI: 10.1007/s11894-003-0004-z.

References
1.
Innes G, Nagafuchi Y, Fuller B, Hobbs K . Increased expression of major histocompatibility antigens in the liver as a result of cholestasis. Transplantation. 1988; 45(4):749-52. DOI: 10.1097/00007890-198804000-00017. View

2.
Bouchard G, Yousef I, Tuchweber B . Influence of oral treatment with ursodeoxycholic and tauroursodeoxycholic acids on estrogen-induced cholestasis in rats: effects on bile formation and liver plasma membranes. Liver. 1993; 13(4):193-202. DOI: 10.1111/j.1600-0676.1993.tb00630.x. View

3.
Chretien Y, Poupon R, Gherardt M, Chazouilleres O, Labbe D, Myara A . Bile acid glycine and taurine conjugates in serum of patients with primary biliary cirrhosis: effect of ursodeoxycholic treatment. Gut. 1989; 30(8):1110-5. PMC: 1434170. DOI: 10.1136/gut.30.8.1110. View

4.
Poupon R, Eschwege E, Poupon R . Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. Interim analysis of a double-blind multicentre randomized trial. The UDCA-PBC Study Group. J Hepatol. 1990; 11(1):16-21. DOI: 10.1016/0168-8278(90)90265-s. View

5.
Calmus Y, Gane P, Rouger P, Poupon R . Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology. 1990; 11(1):12-5. DOI: 10.1002/hep.1840110104. View